Regulus Announces Strategic Update and Corporate Restructuring
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- Wall St falls as Trump's Iran remarks weigh on markets
- Oil jumps around 5% to two-week high after Trump warns of more attacks on Iran
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Amazon launches bond sale seeking at least $25 billion
- Raymond James Starts SpaceX (SPCX) at Strong Buy, PT Street High $800
Regulus Therapeutics (RGLS) PT Lowered to $0.50 at Wells Fargo
July 6, 2018 8:27 AM EDTWells Fargo analyst Jim Birchenough lowered his price target on Regulus Therapeutics (NASDAQ: RGLS) to $0.50 (from $1.50) while maintaining a Market Perform rating following todays interruption of the phase 1 study of anti-miR therapeutic RGLS4326 in autosomal dominant polycystic kidney disease (ADPKD) following unexpected preclinical... More
Regulus Therapeutics (RGLS) Falls 38% as Trading Resumes
July 5, 2018 5:33 PM EDTRegulus Therapeutics (NASDAQ: RGLS) sinks 38% as trading resumes following restructuring and massive job cuts.
... MoreRegulus Therapeutics (RGLS) to Resume Trading at 5:30 pm ET
July 5, 2018 5:03 PM EDTRegulus Therapeutics (NASDAQ: RGLS) to Resume Trading at 5:30 pm ET
... More